Tigecycline

Tigecycline (GAR-936) is a broad-spectrum glycylcycline antibiotic. The mean inhibitory concentration (MIC) of Tigecycline for E. coli (MG1655 strain) is approximately 125 ng/mL[1]. MIC50 and MIC90 are 1 and 2 mg/L for Acinetobacter baumannii (A. baumannii), respectively[2].

Product Specifications

CAS Number

[220620-09-7]

Product Name Alternative

GAR-936

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Antibiotic; Autophagy; Bacterial

Type

Reference compound

Related Pathways

Anti-infection; Autophagy

Applications

COVID-19-immunoregulation

Field of Research

Infection; Cancer

Assay Protocol

https://www.medchemexpress.com/Tigecycline.html

Purity

99.95

Solubility

DMSO : 25 mg/mL (ultrasonic; warming; heat to 60°C) |H2O : 8.33 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

O=C(C(C1=O)=C(O)[C@@H](N(C)C)[C@]2([H])C[C@]3([H])CC4=C(C(C3=C(O)[C@@]21O)=O)C(O)=C(NC(CNC(C)(C)C)=O)C=C4N(C)C)N

Molecular Formula

C29H39N5O8

Molecular Weight

585.65

Precautions

H302, H315, H319, H335

References & Citations

[1]Jitkova Y, et al. A novel formulation of tigecycline has enhanced stability and sustained antibacterial and antileukemic activity. PLoS One. 2014 May 28;9 (5) :e95281.|[2]Falagas ME, et al. Activity of TP-6076 against carbapenem-resistant Acinetobacter baumannii isolates collected from inpatients in Greek hospitals. Int J Antimicrob Agents. 2018 Aug;52 (2) :269-271.

Shipping Conditions

Blue Ice

Storage Conditions

-20°C, 3 years (Powder)

Scientific Category

Reference compound1

Clinical Information

Launched

Citation 01

Adv Ther (Weinh) . 2024 Jan 12.|Anim Dis. 2021;1 (1) :26.|Ann Clin Microbiol Antimicrob. 2024 Aug 20;23 (1) :73.|Antimicrob Agents Chemother. 2019 May 24;63 (6) . pii: e00470-19.|Antimicrob Agents Chemother. 2023 Feb 16;67 (2) :e0145922.|Antimicrob Agents Chemother. 2024 Mar 6;68 (3) :e0112023.|Antimicrob Agents Chemother. 2024 Oct 29:e0094524.|Antimicrob Agents Chemother. 2025 May 23:e0024925.|Authorea. 2025 Sep 17.|Biomed Pharmacother. 2023 Dec 31:169:115856.|Cell Rep. 2025 Nov 25;44 (11) :116496.|Cell. 2025 May 15;188 (10) :2757-2777.e22.|Clin Exp Pharmacol Physiol. 2023 Jul;50 (7) :604-609.|Cureus. 2024 Dec 1;16 (12) :e74917.|EBioMedicine. 2022 Apr;78:103943.|Infect Drug Resist. 2020 Jul 28;13:2617-2629.|Infect Drug Resist. 2021 Jun 30;14:2499-2507.|Infect Drug Resist. 2023 Apr 17:16:2271-2279.|Infect Drug Resist. 2025 Oct 4:18:5239-5247.|Infect Genet Evol. 2025 Sep:133:105780.|Int J Antimicrob Agents. 2018 Aug;52 (2) :269-271.|Int J Antimicrob Agents. 2025 Jun 9:107551.|J Antibiot (Tokyo) . 2022 Aug;75 (8) :463-471.|J Antimicrob Chemother. 2025 Apr 10:dkaf105.|J Appl Microbiol. 2025 Apr 17:lxaf093.|Microb Pathog. 2020 Dec;149:104502.|Microbiol Spectr. 2023 Feb 14;11 (1) :e0323822.|Microbiol Spectr. 2023 Jun 15;11 (3) :e0071823.|Microbiol Spectr. 2025 Mar 19:e0134424.|Microorganisms. 2024 Mar 13;12 (3) :575.|Nat Commun. 2022 Mar 2;13 (1) :1116.|Nat Commun. 2024 Jun 28;15 (1) :5481.|Naunyn Schmiedebergs Arch Pharmacol. 2025 Oct 29.|SLAS Discov. 2020 Sep;25 (8) :895-905.|Vet Microbiol. 2024 May:292:110046.|World J Microbiol Biotechnol. 2024 Jun 6;40 (8) :233.|Ann Lab Med. 2021 May 1;41 (3) :293-301.|Emerg Microbes Infect. 2024 Dec;13 (1) :2321981.